Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 60

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 60
---
 Agreement.

(d) .
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any
provision of this Agreement in any other jurisdiction.

(e) . The Transaction Documents supersede all other prior oral or written agreements between the Investor, the Company, their
affiliates and Persons acting on their behalf with respect to the subject matter thereof, and this Agreement, the other Transaction Documents
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein
and, except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant
or undertaking with respect to such matters. The Company acknowledges and agrees that is has not relied on, in any manner whatsoever,
any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents.

| -32- |

(f) .
Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing and
will be deemed to have been delivered and received: (i) upon receipt when delivered personally; (ii) upon receipt when sent by email (provided
confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one Business
Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the
same. The addresses for such communications shall be:

| If to the Company:                                           |
| Biodexa Pharmaceuticals PLC                                  
 1 Caspian Point,                                             
 Caspian Way                                                  
 Cardiff, CF10 4DQ, United Kingdom                            
 E-mail:            stephen.stamp@biodexapharma.com           
 Attention:     Stephen Stamp,                                
 CEO                                                          |
| With a copy to (which shall                                  
 not constitute notice or service of process):                |
| Mintz, Levin, Cohn, Ferris,                                  
 Glovsky and Popeo, P.C.                                      
 One Financial Center                                         
 Boston, MA 02111                                             
 E-mail:            JSMcCaffrey@mintz.com                     
 Attention:     Jason McCaffrey, Esq.                         |
| If to the Investor:                                          |
| C/M Capital Master Fund, LP                                  
 1111 Brickell